RUNX2 Activators
RUNX2 activators are a diverse group of chemicals that exert their effects through various signaling pathways, ultimately leading to the activation of RUNX2 and promoting osteoblast differentiation and bone formation. These compounds indirectly modulate the Wnt, cAMP, ERK/MAPK, mevalonate, and NF-κB pathways, among others, influencing the expression and activity of RUNX2. PTHrP, through its action on the Wnt pathway, stimulates RUNX2 expression and osteoblast differentiation. Chemicals like 6-Bromoindirubin-3'-oxime and lithium chloride inhibit GSK-3β, indirectly activating the Wnt pathway and promoting RUNX2 activity. Prostaglandin E2 activates the cAMP pathway, contributing to the expression and function of RUNX2.
Leptomycin B, ICG-001, and TAK-242 modulate the Wnt and NF-κB pathways, indirectly influencing RUNX2 activation. Sphingosine-1-phosphate activates the ERK/MAPK pathway, leading to increased expression and activity of RUNX2. Alendronate and zoledronic acid, as bisphosphonates, indirectly activate the mevalonate pathway, promoting RUNX2-mediated osteoblast differentiation. Butyrate, a short-chain fatty acid, inhibits HDACs, indirectly promoting RUNX2 expression and contributing to osteoblast differentiation. Gambogic acid inhibits NF-κB, leading to increased RUNX2 activity.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
GSK-3 Inhibitor IX | 667463-62-9 | sc-202634 sc-202634A sc-202634B | 1 mg 10 mg 50 mg | $58.00 $188.00 $884.00 | 10 | |
6-Bromoindirubin-3'-oxime is a compound that inhibits GSK-3β, a negative regulator of the Wnt pathway. By inhibiting GSK-3β, this chemical indirectly activates Wnt signaling, leading to increased expression and activity of RUNX2 and promoting osteoblast differentiation and bone formation. | ||||||
PGE2 | 363-24-6 | sc-201225 sc-201225C sc-201225A sc-201225B | 1 mg 5 mg 10 mg 50 mg | $57.00 $159.00 $275.00 $678.00 | 37 | |
Prostaglandin E2 (PGE2) is involved in the cAMP signaling pathway. By activating the cAMP pathway, PGE2 indirectly promotes the expression and activity of RUNX2, contributing to osteoblast differentiation and bone formation. | ||||||
Lithium | 7439-93-2 | sc-252954 | 50 g | $214.00 | ||
Lithium chloride inhibits GSK-3β, a negative regulator of the Wnt pathway. Through GSK-3β inhibition, lithium chloride indirectly activates Wnt signaling, leading to increased expression and activity of RUNX2, promoting osteoblast differentiation and bone formation. | ||||||
Leptomycin B | 87081-35-4 | sc-358688 sc-358688A sc-358688B | 50 µg 500 µg 2.5 mg | $107.00 $416.00 $1248.00 | 35 | |
Leptomycin B inhibits nuclear export and stabilizes β-catenin, a key component of the Wnt pathway. By stabilizing β-catenin, leptomycin B indirectly activates Wnt signaling, leading to increased expression and activity of RUNX2, promoting osteoblast differentiation and bone formation. | ||||||
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $165.00 $322.00 $570.00 $907.00 $1727.00 | 7 | |
Sphingosine-1-phosphate (S1P) activates the S1P receptor, leading to the activation of the ERK/MAPK pathway. Through ERK/MAPK activation, S1P indirectly promotes the expression and activity of RUNX2, contributing to osteoblast differentiation and bone formation. | ||||||
Alendronate acid | 66376-36-1 | sc-337520 | 5 g | $135.00 | 2 | |
Alendronate is a bisphosphonate that inhibits farnesyl diphosphate synthase (FDPS). By inhibiting FDPS, alendronate indirectly activates the mevalonate pathway, leading to increased prenylation of small GTPases, which can promote the expression and activity of RUNX2, contributing to osteoblast differentiation and bone formation. | ||||||
Resatorvid | 243984-11-4 | sc-476758 | 5 mg | $367.00 | ||
TAK-242 inhibits Toll-like receptor 4 (TLR4) signaling, leading to the suppression of NF-κB activation. By inhibiting NF-κB, TAK-242 indirectly promotes the expression and activity of RUNX2, contributing to osteoblast differentiation and bone formation. | ||||||
Butyric acid | 107-92-6 | sc-214640 sc-214640A | 1 kg 10 kg | $64.00 $177.00 | ||
Butyrate is a short-chain fatty acid that inhibits histone deacetylases (HDACs). By inhibiting HDACs, butyrate indirectly activates the transcription of genes, including RUNX2, contributing to osteoblast differentiation and bone formation. | ||||||
Gambogic Acid | 2752-65-0 | sc-200137 sc-200137A sc-200137B sc-200137C sc-200137D | 5 mg 25 mg 100 mg 500 mg 1 g | $87.00 $248.00 $427.00 $734.00 $1255.00 | 5 | |
Gambogic Acid inhibits the NF-κB pathway by targeting IκB kinase (IKK). By inhibiting NF-κB, gambogic acid indirectly promotes the expression and activity of RUNX2, contributing to osteoblast differentiation and bone formation. | ||||||
Zoledronic acid, anhydrous | 118072-93-8 | sc-364663 sc-364663A | 25 mg 100 mg | $92.00 $256.00 | 5 | |
Zoledronic Acid is a bisphosphonate that inhibits farnesyl diphosphate synthase (FDPS). By inhibiting FDPS, zoledronic acid indirectly activates the mevalonate pathway, leading to increased prenylation of small GTPases, which can promote the expression and activity of RUNX2, contributing to osteoblast differentiation and bone formation. | ||||||